Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2007

AtheroGenics’ Shares Sink after a Disappointing Phase III for Atherosclerosis Drug

  • AtheroGenics’ candidate to treat atherosclerosis failed to meet its endpoint in Phase III evaluation. The company reports, however, that certain predefined endpoints were attained.

    The company’s shares fell 61% to open trading at $3.04.

    The ARISE study did not show a difference from placebo in its composite primary endpoint. However, the AtheroGenics says, there was a reduction in the composite of hard atherosclerotic clinical endpoints, composed of cardiovascular death, myocardial infarction, and stroke, as well as an improvement in several key diabetes parameters.

    After completion of the final analysis, AstraZeneca, who is collaborating with AtheroGenics on this compound, has 45 days to decide whether or not to continue with the collaboration.

    The Phase III, double-blind, placebo-controlled trial was conducted in over 6,100 patients with a recent acute coronary syndrome. The trial was conducted in 259 cardiac centers in the U.S., U.K., Canada, and South Africa.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »